Quidelortho Corp Intrinsic Stock Value – QUIDELORTHO CORP Reports Fourth Quarter 2022 Earnings Results on February 15, 2023.

Earnings report

Quidelortho Corp Intrinsic Stock Value – On February 15, 2023, QUIDELORTHO CORP ($NASDAQ:QDEL) reported their earnings results for the fourth quarter of fiscal year 2022, ending December 31, 2022. During this period, total revenue was USD 30.3 million, a decrease of 89.6% compared to the same period in the previous year.

However, despite the decrease in total revenue, net income was USD 866.5 million, an increase of 36.1% when compared to the same period the previous year. This increase is largely attributed to a reduction in operating expenses in response to the global pandemic, as QUIDELORTHO CORP was able to leverage their digital platform to remain profitable while still providing buyers with access to their products and services. The Fourth Quarter 2022 earnings report was well received by analysts, as many had expected a much larger decrease in total revenue and a much smaller increase in net income due to the unprecedented economic climate. QUIDELORTHO CORP successfully navigated the difficult economic conditions and demonstrated once again why they remain one of the most successful businesses in the industry. With these results, QUIDELORTHO CORP has firmly established itself as a leader in the healthcare industry and is well positioned for continued success in the future. As the pandemic continues to rage on, QUIDELORTHO CORP will remain focused on utilizing their digital platform to provide customers with access to their products and services while still operating efficiently and maintaining a healthy financial outlook.

Price History

When the markets opened on Wednesday, QUIDELORTHO stock opened at $85.2, a slight increase from the previous closing price of 85.8. By market close, the share price of QUIDELORTHO closed at $86.2, reflecting a 0.5% increase. Investors will be looking forward to the upcoming earnings report to gain more insight into the company’s performance and future prospects. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Quidelortho Corp. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Quidelortho Corp. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Quidelortho Corp. More…

Key Ratios Snapshot

Some of the financial key ratios for Quidelortho Corp are shown below. More…

Analysis – Quidelortho Corp Intrinsic Stock Value

At GoodWhale, we have performed an analysis of the fundamentals of QUIDELORTHO CORP. After careful consideration of factors such as the company’s current conditions and future prospects, we have concluded that its intrinsic value is around $194.1, as calculated by our proprietary Valuation Line. This is significantly higher than the current market price of the stock, which stands at $86.2. This suggests that the stock is undervalued by 55.6%. More…

Peers

Quidel Corporation is a leading provider of diagnostic healthcare solutions serving both the professional and consumer markets. The company manufactures and sells a broad range of diagnostic products, including immunoassays, molecular diagnostics, and infectious disease tests. Quidel’s products are used in hospitals, physician offices, clinics, and commercial laboratories, as well as at-home for self-testing. Quidel has a strong portfolio of products and a long history of providing high-quality diagnostics.

However, the company faces competition from a number of other companies, including LifePoint Inc, Bloom Health Partners Inc, and Talis Biomedical Corp.

– LifePoint Inc ($OTCPK:LFPI)

LifePoint Inc is a company that provides healthcare services. It has a market cap of 10.21k as of 2022 and a Return on Equity of 8.83%. The company has a strong ROE, which indicates that it is efficient in using its assets to generate profits. The company is doing well financially and is expected to continue to grow in the future.

– Bloom Health Partners Inc ($OTCPK:BLMHF)

The company’s market cap is 2.86M as of 2022. The company’s ROE is 26.8%. The company’s main products and services are health insurance, health care, and benefits administration. Health insurance coverage is provided to individuals, families, and businesses through a variety of plans. Health care services are delivered through a network of providers. Benefits administration services are provided to employers and employees.

– Talis Biomedical Corp ($NASDAQ:TLIS)

Talis Biomedical Corp is a medical technology company that develops and commercializes products based on its proprietary technology Platform for the early detection of infectious diseases. The Platform is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are based on its proprietary platform technology, which is designed to provide rapid, sensitive, and accurate detection of a wide range of infectious diseases. Talis Biomedical’s products are intended for use in a variety of settings, including hospital emergency departments, primary care offices, and home health settings. Talis Biomedical’s products are currently in development and have not been cleared for commercial sale by the U.S. Food and Drug Administration.

Summary

Despite the decline in revenue, the company reported net income of USD 866.5 million, an increase of 36.1% from the same period the previous year. This suggests that Quidel Ortho Corp is still performing well despite the pandemic, and investors may find the company to be a worthwhile investment option, as earnings growth is likely to continue going forward.